Cannabis Science President & CEO Mr. Raymond C. Dabney Awarded The 2018 Harvard Global Health Catalyst Industry Leader Award May 25-27th at Harvard Medical School, Boston, MA
Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that Mr. Raymond C. Dabney, the Company’s President, Chief Executive Officer (CEO), and Co-founder, has been named a recipient of the esteemed 2018 Harvard Global Health Catalyst (GHC) Industry Leader Award. This prestigious award was recently announced by the organizing committee of the 2018 GHC Summit and will be presented during the Summit scheduled for May 25-27that Harvard Medical School in Boston, MA.
According to the Harvard GHC Summit Organizing Committee, Mr. Dabney is being recognized for “…establishing groundbreaking partnerships with African institutions to close the cancer and pain divide, investigating safe phytomedicine alternatives to opioids, and providing support for the development of phytomedicines to reduce global health disparities.”
To view the announcement of Mr. Dabney’s award, please visit:
https://www.globalhealthcatalystsummit.org/news; and
https://docs.wixstatic.com/ugd/7c636d_5b7e6e00633943989bc4d1af010b285f.pdf
“I am honored and humbled to be named a recipient of such a prestigious Harvard Award. Being named and acknowledged for our work amongst the ranks of all the other Harvard Global Health Catalyst Industry Leader Award winners and other renowned critical ailment researchers around the world, pretty much says it all,” stated Mr. Dabney. “Again, I believe firmly that this award validates the work of Cannabis Science and our research collaborators, and signals that we are definitely on the right path as we develop cannabinoid-based medicines to treat a number of critical ailments, including Cancers, Chronic pain, HIV/AIDS, Post Traumatic Stress Syndrome (PTSD), Neurological disorders, Chronic Obstructive Pulmonary Disease (COPD), and Arthritis.”
Mr. Dabney will also be the keynote speaker during the Phytomedicines Session on May 26th. The theme of this session is From Farm to Bedside: Advancing Clinical Translation of Medical Cannabis and Other Phytomedicines for Global Health. Mr. Dabney will discuss the development of effective cannabinoids and the creation of the Cannabis Science Global Consortium, a research and development framework and platform to cooperate and collaborate with stakeholders worldwide. The Cannabis Science Global Consortium links universities, foundations, corporations, and individuals to share research, ideas, and other relevant information, as well as to implement a cutting-edge research program to develop medicines and delivery mechanisms from bench-to-bedside. The Global Consortium also enables the Company to more strategically coordinate its initiatives, including those focused on education, job creation, and skills training.
The Phytomedicines Session will provide a forum for an important conversation during the Harvard GHC Summit, given that over 26 states in the U.S. and a growing number of countries around the world have now legalized medical cannabis. Frontier research is now making it possible for cannabinoids to be delivered directly to disease sites/targets with minimal or no side effects, which have hampered clinical translation. At the same time global health collaborations are beginning to bring plant-based medicines from low and middle-income countries to the world stage as low-cost remedies. The Phytomedicines Session will focus on the potential use of Medical Cannabis in treating cancers, and closing the global pain divide, and on leading edge international collaborations to accelerate research and clinical translation of phytomedicines in global health.
Cannabis Science’s Chief Medical Officer (CMO), Dr. Allen Herman, will moderate the Phytomedicines Session. Dr. Herman will also present on the role of cannabinoids in reducing the pain therapeutic divide between developed and developing countries, and CBIS’ research and development plan. “The Harvard GHC Summit provides Cannabis Science with a unique platform to share information on our research and drug-development initiatives with global stakeholders,” stated Dr. Herman. “As we implement our ‘farm-to-bedside’ approach, we welcome the opportunity to collaborate with leaders from around the world who are actively involved in relevant research, development, and clinical trials.”
For information on the upcoming 2018 Harvard GHC Summit, please visit:
https://www.globalhealthcatalystsummit.org/
For information on the Phytomedicines Session to be held on May 26th, please visit:
https://www.globalhealthcatalystsummit.org/medical-cannabis
Cannabis Science’s funded research currently focuses on the clinical applications of cannabinoids in cancer treatment and pain management. The Company’s research will expand to investigate the effectiveness of cannabinoid treatment in an increasing array of cancers, especially difficult to treat cancers and those with high fatality rates; develop novel targeted delivery methods in the use of cannabinoids, and – with advances in bioinformatics, computer science, and pharmacology – explore the mechanisms of action of cannabinoids in the management of disease. Cannabis Science’s initial results point to the importance of drug delivery systems and the impact of co-interventions, and were published in September 2017. The Company’s peer-reviewed article in Frontiers in Oncology, “Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids”, has been viewed more than 11,000 times, and has more views than 96% of all Frontiers’ articles.
To view the article in Frontiers in Oncology:
https://www.frontiersin.org/articles/10.3389/fonc.2017.00208/full
To view the article’s impact:
http://loop-impact.frontiersin.org/impact/article/290549#totalviews/views
Cannabis Science’s second article, “Enhancing the Therapeutic Efficacy of Cancer Treatment with Cannabinoids”, was published in Frontiers in Oncology on April 24, 2017. To view the article, please visit https://www.frontiersin.org/articles/10.3389/fonc.2018.00114/full.
The 2018 Harvard GHC Industry Leader Award recognized Mr. Dabney’s collaborations with African institutions as part of Cannabis Science’s Africa Initiative. In 2016, the Company launched this initiative with the goal of helping to accelerate economic development throughout Africa, with a focus on educational and job-creation initiatives. In implementing its work in Africa, Cannabis Science collaborates closely with the Constituency for Africa (CFA). For over 26 years, CFA has established itself as one of the leading, non-partisan organizations focused on educating and mobilizing the American public and the African Diaspora in the U.S. on U.S.-Africa policy. Mr. Dabney is a Member of CFA’s Board of Directors, and a Co-chair of CFA’s African Healthcare Infrastructure Committee. The key objectives of Cannabis Science’s African Initiative include:
Agriculture & Drug Development: Cannabis Science plans to establish viable operations throughout Africa inclusive of growing operations, research and drug development, multi-center clinical trials, manufacturing and sales. Cannabis Science intends to supply the African market with cannabinoid-based medicines to treat a number of indications, as well as to export medicines from Africa to other markets worldwide.
Healthcare Infrastructure: The Company will help establish hospitals, health centers, and related educational facilities, to also include drug development.
Food Safety:Cannabis Science operates from the farm to the table. In that light, food security begins with sound agricultural practices that produce sufficient food for consumption and that are designed to reduce poverty. Water management and safety, food preservation and safety are additional core components of sound agriculture and food policy. Environmental factors are important risk factors for infectious disease epidemics. Cannabis Science also believes that rigorous waste management and sanitation are vital epidemic control mechanisms.
Political Environment: The Company recognizes the need to impact policy, regulatory, and jurisdictional contexts that outline public healthcare; as well as agricultural, educational and training contexts that in turn define the health and economic well-being of all communities.
Education and Job Creation:At the heart of job creation is education and training. Sustainable models of education and training are associated with important areas of development, including industrial sectors such as drug development/treatments, agriculture/food safety, communications, investments, and engaging political environments.
Technology and Communication: Satellite, Internet, mechanical device development, and cellphone infrastructure are all important components of healthcare, educational, and economic development. In addition, dynamic media exposure defines how communities perceive themselves and respond to their problems.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, the characterization of medicines, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.